

## Press Release

### **Magnisense receives €1.2 million in financing from Bpifrance for its innovative MI<sup>2</sup> project to develop emergency diagnostic tests for cardiovascular diseases**

Paris, February 2, 2015 –Bpifrance (the French public investment bank) announce the selection of the MI<sup>2</sup> (MIAték® Instrumentation & Innovation) project of Magnisense to receive €1.2 million in financing for innovation over a two-year period.

The launch of the MI<sup>2</sup> project will enable Magnisense to bring its products to market faster while boosting their competitive edge and intellectual property: emergency diagnostic tests for cardiovascular diseases. The MI<sup>2</sup> project also aims to drive the potential of its proprietary MIAték® technology, based on magnetic nanomaterials, in its product pipeline.

Bpifrance has been a partner to Magnisense and supported its development for several years. The bank has cofinanced a number of its research and development projects, attesting to the innovation and appeal of its technology, development plan and products.

The selection of the MI<sup>2</sup> project by Bpifrance comes as Magnisense inaugurated its new R&D laboratory on January 30, 2015 in Dardilly, near Lyon, France. Located at the Le Campus site, the facility features new offices suited to the company's expansion. For the event, Magnisense brought together its leading partners, with representatives from Bpifrance and from *Assistance Publique Hôpitaux de Paris* (AP-HP, the Paris Public Hospitals Group, with Dr. Etienne Gayat from the Anesthesia and Reanimation Department, Lariboisière Saint Louis Hospital in Paris), along with its partners from regional and national academic institutions and industry.

In December 2014, Magnisense was also awarded the EIP (*"Entreprise Innovante des Pôles"* or Innovative Cluster Company) label by a committee of private equity professionals made up of experts from the Medicen Paris Region business cluster, representatives from investment funds, business angels and Bpifrance representatives as part of DEFI Biotech Santé, a biotech and healthcare business development and support program.

*"The support offered by Bpifrance to Magnisense over the years and through the MI<sup>2</sup> project has been extremely valuable and contributed significantly to the company's financial and technological development. By initiating this new project, we can bring our products to market faster,"* states Magnisense CEO Lyse Santoro.

Claude Sabatin, Bpifrance innovation representative, adds, *"Magnisense's MI<sup>2</sup> project immediately caught our interest, as it responds to the urgent need for decentralized emergency diagnostics in healthcare, while offering attractive commercial potential. By coming on board this project, Bpifrance supports its innovation portfolio even further."*

### About Bpifrance

**Bpifrance** is a subsidiary of Caisse des Dépôts et de l'État and the trusted partner of entrepreneurs. The French public investment bank finances businesses from the seed phase to stock exchange listing, through loans, guarantees and equity. **Bpifrance** accompanies firms developing export activities and provides support services for their innovation and acquisition projects, in partnership with Business France and Coface.

**Bpifrance** offers businesses a financing continuum, present in every key phase of business development and an offer adapted to the specific regional context.

With a network of 42 regional offices (90% of decisions are made at the regional level), **Bpifrance** serves entrepreneurs to boost economic competitiveness. **Bpifrance** acts in support of public policy established by the State and the Regions to meet three goals:

- accompany businesses in their growth;
- prepare tomorrow's competitive landscape;
- develop an ecosystem that favours entrepreneurship.

**Bpifrance** acts as a powerful partner to businesses, one that is on hand and able to respond efficiently to all of their financing, innovation and investment needs.

Find out more at: [www.bpifrance.fr](http://www.bpifrance.fr) and [www//investissementsdavenir.bpifrance.fr/](http://www//investissementsdavenir.bpifrance.fr/)

Follow us on Twitter: @bpifrance

**About Magnisense:** Magnisense is a private company that designs, develops and records emergency diagnostic tests for cardiovascular diseases, in particular myocardial infarction, for commercial use. These proprietary tests use Magnisense's groundbreaking MIAtek® technology based on magnetic nanomaterials, which is protected internationally by five families of patents issued in Europe and the United States. The tests meet the needs of hospital emergency physicians and cardiologists in all respects: they produce quantitative and sensitive amounts of cardiac markers directly in whole blood in 15 minutes, using a robust, portable and decentralized instrument available at a competitive price. Magnisense was founded by the inventor of the technology and a group of business angels. The main investors are Daniel Bernard and Jean-Patrick Voisin. Its head office is in Paris, and its R&D laboratory, "Le Campus", is located in the Lyonbiopôle life sciences cluster. Magnisense aims to become a leader in emergency cardiac diagnostics by commercializing competitive tests that address healthcare and economic issues.

[www.magnisense.com](http://www.magnisense.com)

**About cardiovascular diseases:** Cardiovascular diseases are the leading cause of death worldwide, killing 17 million people every year. As the population ages, this figure is expected to reach 24 million by 2030. Given the sharp increase in cardiovascular accidents and the associated direct and indirect costs, a genuine medical need has developed for rapid, robust, portable and economical emergency diagnostic tests.

### Press contacts:

Bpifrance: [vanessa.godet@bpifrance.fr](mailto:vanessa.godet@bpifrance.fr) – Tel.: +33 (0)1 41 79 84 33

Magnisense: [info@magnisense.com](mailto:info@magnisense.com) – Tel.: +33 (0)1 45 62 80 00

Alize RP: Caroline Carmagnol [caroline@alizerp.com](mailto:caroline@alizerp.com) – Tel.: +33 (0)1 44 54 36 66 / Sophie

Colin [scolin@alizerp.com](mailto:scolin@alizerp.com) – Tel.: +33 (0)1 44 54 36 62